Trial · NCT00612430

Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

NCT00612430, Phase 2, Completed, Duke University; results first posted 2013-07-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Ph II Bevacizumab + Etoposide for Pts w Recurrent MG. Trials, record NCT00612430. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00612430

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
NCT number: NCT00612430
Status: Completed
Phases: Phase 2
Enrollment: 59 participants, actual
Lead sponsor: Duke University
Conditions: Glioblastoma, Gliosarcoma
Interventions: Bevacizumab and Etoposide
First posted: 2008-02-11
Last updated: 2013-08-12
Results first posted: 2013-07-26

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	6 Month Progression-Free Survival (PFS)	6 months	Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression. Progression was defined as greater than or equal to a 25% increase in the product of the largest perpendicular diameters of any enhancing lesion or any new enhancing tumor on MRI scans.
Secondary	Objective Response Rate	2 years	The percentage of participants with complete or partial response as determined by the following criteria: complete response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination; partial response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination. A confirmation of response was not required.
Secondary	Safety of Study Treatment Regimen	2 years	Number of participants experiencing a non-hematologic toxicity ≥ grade 3 that was possibly, probably, or definitely related to study treatment.
Secondary	Median Progression-Free Survival	Patients were followed for a median of 91.4 weeks	Time in weeks from the start of study treatment to the date of first progression, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve.
Secondary	Median Overall Survival (OS)	median of 91.4 weeks	Time in weeks from the start of study treatment to date of death due to any cause. Patients alive as of the last follow-up had OS censored at the last follow-up date. Median OS was estimated using a Kaplan-Meier curve.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	6 Month Progression-Free Survival (PFS)	6 months	percentage of participants	NUMBER
SECONDARY	Objective Response Rate	2 years	percentage of participants	NUMBER
SECONDARY	Safety of Study Treatment Regimen	2 years	participants	NUMBER
SECONDARY	Median Progression-Free Survival	Patients were followed for a median of 91.4 weeks	weeks	MEDIAN
SECONDARY	Median Overall Survival (OS)	median of 91.4 weeks	weeks	MEDIAN

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
6 Month Progression-Free Survival (PFS)	Grade III	41	95% Confidence Interval 24 to 57	percentage of participants
6 Month Progression-Free Survival (PFS)	Grade IV	44	95% Confidence Interval 26 to 62	percentage of participants
Objective Response Rate	Grade III	24		percentage of participants
Objective Response Rate	Grade IV	23		percentage of participants
Safety of Study Treatment Regimen	Grade III	9		participants
Safety of Study Treatment Regimen	Grade IV	13		participants
Median Progression-Free Survival	Grade III	24	95% Confidence Interval 16 to 33	weeks
Median Progression-Free Survival	Grade IV	18	95% Confidence Interval 13 to 40	weeks
Median Overall Survival (OS)	Grade III	63.1	95% Confidence Interval 36 to NA	weeks
Median Overall Survival (OS)	Grade IV	46.4	95% Confidence Interval 25 to 70	weeks

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Grade III	32
Overall Study	STARTED	Grade IV	27
Overall Study	COMPLETED	Grade III	32
Overall Study	COMPLETED	Grade IV	27
Overall Study	NOT COMPLETED	Grade III	0
Overall Study	NOT COMPLETED	Grade IV	0

Source ClinicalTrials.gov

Adverse events316

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Grade III	10	32
other	Anemia	Blood and lymphatic system disorders	Grade IV	19	27
other	Cardiac disorders - Other, specify: S1-S2 with grade II/IV murmur	Cardiac disorders	Grade III	0	32
other	Cardiac disorders - Other, specify: S1-S2 with grade II/IV murmur	Cardiac disorders	Grade IV	1	27
other	Cardiac disorders - Other, specify: Variable Heart Rate	Cardiac disorders	Grade III	1	32
other	Cardiac disorders - Other, specify: Variable Heart Rate	Cardiac disorders	Grade IV	0	27
other	Cardiac disorders - Other, specify: Angina	Cardiac disorders	Grade III	1	32
other	Cardiac disorders - Other, specify: Angina	Cardiac disorders	Grade IV	0	27
other	Hearing impaired	Ear and labyrinth disorders	Grade III	2	32
other	Hearing impaired	Ear and labyrinth disorders	Grade IV	0	27

1 to 10 of 316Source ClinicalTrials.gov

See all 316 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Grade III
Total, all-cause mortality	Grade IV
Total, other adverse events	Grade III	31	32
Total, other adverse events	Grade IV	27	27
Total, serious adverse events	Grade III	2	32
Total, serious adverse events	Grade IV	3	27

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19920819	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Grade III vs Grade IV: Safety of Study Treatment Regimen	Trial comparisons
Grade III vs Grade IV: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00612430

GET https://conductscience.org/api/trials/v1/NCT00612430/events?page=2

API reference For AI assistants